North American Generic Drugmakers Call for Rejection of New Exclusivity Period for Biologics

Statement of the Association for Accessible Medicines, Canadian Generic Pharmaceutical Association, and Mexican Association of Generic Medicines on the Announcement U.S.-Mexico Understanding on Biologic Exclusivity

The announced trade understanding between the U.S. and Mexico to extend brand name biologic data protection to ten years will harm patients who seek more affordable medicines. This provision would harm the growing biosimilar industry, which aims to provide price competition to some of the most expensive prescription drugs and allow patients to benefit from affordable medicines. The U.S., Mexico and Canada should reject these provisions, which would benefit brand name drug companies to the detriment of public health and the affordability of medical care.

Rachel Schwartz 
202.249.7147 (o)
202.251.8881 (c)